ESR1 and breast cancer: Out of the total breast cancers, approximately 30 to 40 % of women with breast cancer belong to estrogen receptor alpha negative (ERα−) breast cancer, which is characterized by more aggressive phenotype, poor prognosis and recalcitrance to conventional hormonal therapies [4].